Fusion Antibodies

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services

- Antibody Engineering Services

- Antibody sequencing Services

- Protein Expression & Purification Services

- Monoclonal Antibody services BLAST & Standard

- cGMP Services

Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.

Dunmurry, GB
14 (est)+8%
Fusion Antibodies was founded in 2001 and is headquartered in Dunmurry, GB

Fusion Antibodies Locations

Dunmurry, GB

Fusion Antibodies Metrics

Fusion Antibodies Summary

Founding Date


Total Funding

$2.5 M

Latest funding size

$2.5 M

Time since last funding

over 9 years


Fusion Antibodies's latest funding round of $2.5 M was in July 2007. In total, Fusion Antibodies has raised $2.5 M.

Fusion Antibodies Financials

Fusion Antibodies's revenue was £723 K in FY, 2014 which is 78.53% increase from the previous period.
FY, 2013FY, 2014


£405 K£723 K

Revenue growth, %


Cost of sales

£324 K£365 K

Gross profit

£80.8 K£358 K

Gross profit Margin, %


Operating expense total

£554 K£477 K
100% of current employees of Fusion Antibodies are male.

Fusion Antibodies Online Presence

Fusion Antibodies News

Fusion Antibodies Company Life

You may also be interested in